Efficacy of afatinib treatment for lung adenocarcinoma harboring exon 18 delE709_T710insD mutation
| Autor: | Naofumi Hara, Chihiro Ando, Katsuyuki Kiura, Atsuko Hirabae, Eiki Ichihara, Takahiro Umeno, Yoshinobu Maeda, Takamasa Nakasuka, Yoshitaka Iwamoto |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
0301 basic medicine Cancer Research Lung Neoplasms Afatinib Adenocarcinoma of Lung medicine.disease_cause 03 medical and health sciences Exon 0302 clinical medicine medicine Humans Radiology Nuclear Medicine and imaging Epidermal growth factor receptor Lung cancer Protein Kinase Inhibitors Aged Mutation Lung biology business.industry Cancer Exons General Medicine Middle Aged medicine.disease ErbB Receptors Treatment Outcome 030104 developmental biology medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Quinazolines Cancer research biology.protein Adenocarcinoma Female Tomography X-Ray Computed business medicine.drug |
| Zdroj: | Japanese Journal of Clinical Oncology. 49:786-788 |
| ISSN: | 1465-3621 |
| Popis: | Exon 18 delE709_T710insD is an extremely rare mutation in epidermal growth factor receptor (EGFR) in non-small-cell lung cancer (NSCLC); the efficacy of EGFR tyrosine kinase inhibitors against this mutation remains unclear. In this case report, we report a case of NSCLC harboring EGFR exon 18 delE709_T710insD that was not detected by a commercially available assay, but was detected by a next-generation sequencing cancer panel. A 56-year old female patient with advanced NSCLC was diagnosed as EGFR-mutation-negative using the PNAClamp method. ALK rearrangement was also absent and she received cytotoxic chemotherapies. Clinical characteristics, including adenocarcinoma histology and no history of smoking, implied the presence of a driver mutation, so a next-generation-sequencing Oncomine® Cancer Research Panel was conducted in the patient’s clinical course and the EGFR exon 18 delE709_T710insD mutation was detected. The patient started afatinib as sixth-line treatment and her pulmonary lesion significantly decreased in size. Afatinib was continued for 7 months until disease progressed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|